Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Scientists discover a surprising link between vitamin C and cancer survival | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-10-20

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

One claim goes further than the study.

  • 3 supported
  • 1 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

One claim overstates the study. Three of four check out.

  • 3 supported
  • 1 overstated
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedPatients who received vitamin C had fewer adverse events during the study and follow-up, and an exploratory analysis found they were significantly more likely to be alive after about three years than those who took placebo.View evidenceHide evidence

As statedapproximately three years of follow-up

Why this verdict

The survival portion is broadly supported as an exploratory finding: overall survival was significantly longer with vitamin C in the abstract-level profile. However, the claim overstates or imprecisely frames the harms finding: the profile reports fewer serious adverse events, not fewer adverse events generally, and describes them as a secondary outcome with limited abstract-level detail. The phrase “during the study and follow-up” and “after about three years” are not verifiable from the supplied abstract profile, which does not provide follow-up duration, censoring, event counts, or detailed harms timing.

1

Study evidence

Fewer participants experienced serious adverse events in the vitamin C arm than in the placebo arm during the treatment period.Counts: 18/55 (33%) vs 30/53 (57%); risk difference ≈ -24 percentage points; relative risk ≈ 0.58 (33%/57%).

“secondary outcomes included ... fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%])”
2

Study evidence

In exploratory analyses of the randomized cohort during long-term follow-up, overall survival was significantly longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17–0.71); p = 0.0025

“In exploratory analyses, overall survival was significantly longer with VitC (hazard ratio, 0.35; 95% CI, 0.17 to 0.71; p = .0025).”
Claim 2 of 4SupportedA phase 2 EVITA clinical trial suggests that taking vitamin C daily could improve survival in people with precancerous blood disorders and early-stage blood cancers.View evidenceHide evidence

Why this verdict

The abstract-level profile reports an exploratory overall-survival analysis favoring vitamin C over placebo (HR 0.35; 95% CI 0.17–0.71; p = 0.0025) in the EVITA phase 2 randomized trial. The headline is hedged with “suggests” and “could,” which is important because survival was exploratory rather than the primary endpoint. The claim is supported at this depth, provided it is understood as hypothesis-generating rather than definitive.

1

Study evidence

In exploratory analyses of the randomized cohort during long-term follow-up, overall survival was significantly longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17–0.71); p = 0.0025

“In exploratory analyses, overall survival was significantly longer with VitC (hazard ratio, 0.35; 95% CI, 0.17 to 0.71; p = .0025).”
Claim 3 of 4SupportedThe randomized, double-blind, placebo-controlled study enrolled 109 patients with clonal cytopenia of undetermined significance (CCUS) or myelodysplastic syndrome (MDS), and participants received 1,000 mg of oral vitamin C or placebo daily for 12 months.View evidenceHide evidence

As stated109 patients; 1,000 mg daily; 12 months

Why this verdict

The profile supports the trial design and core methods: EVITA was a phase 2, randomized, double-blind, placebo-controlled trial; 109 adults with CCUS or lower-risk myeloid malignancies were randomized 1:1 to oral vitamin C 1000 mg/day or placebo for 12 months. The supplied profile uses the broader term “lower-risk myeloid malignancies” rather than detailing every diagnostic subtype, but the trial-description elements in the claim are otherwise directly supported.

1

Study evidence

No difference in the prespecified primary endpoint (median clonal growth rate from baseline to end of 12-month treatment) between vitamin C and placebo.-0.016 (95% CI -0.096 to 0.064); p = .70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
Claim 4 of 4SupportedVitamin C did not significantly affect the rate at which abnormal blood cells expanded, and the researchers say the survival finding must be verified in a larger phase 3 clinical trial.View evidenceHide evidence

Why this verdict

The profile states that the prespecified primary endpoint—median clonal growth rate from baseline to the end of 12-month treatment—did not differ between groups. It also labels the overall-survival result as exploratory and says the signals support a rationale for a phase 3 trial, matching the story’s caveat that the survival finding needs confirmation.

1

Study evidence

No difference in the prespecified primary endpoint (median clonal growth rate from baseline to end of 12-month treatment) between vitamin C and placebo.-0.016 (95% CI -0.096 to 0.064); p = .70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
2

Study evidence

In exploratory analyses of the randomized cohort during long-term follow-up, overall survival was significantly longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17–0.71); p = 0.0025

“In exploratory analyses, overall survival was significantly longer with VitC (hazard ratio, 0.35; 95% CI, 0.17 to 0.71; p = .0025).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Secondary inflammatory cytokine trajectory differences were reported as a biological-activity signal.

    The profile identifies cytokine trajectory differences as a secondary outcome, but the story claims provided do not mention this biological-readout result.

    From Double-blind randomized placebo-controlled phase 2 trial with longitudinal biomarker assessment

5 things the story did carry across
  • EVITA trial design: phase 2, double-blind, randomized, placebo-controlled trial of oral vitamin C 1000 mg/day versus placebo for 12 months in 109 adults with CCUS or lower-risk myeloid malignancies.
  • Primary endpoint was clonal growth rate from baseline to end of treatment, and it was negative: no significant difference between vitamin C and placebo.
  • Serious adverse events were fewer in the vitamin C group, reported as a secondary outcome: 18/55 versus 30/53.
  • Exploratory overall-survival analysis favored vitamin C, with HR 0.35, 95% CI 0.17–0.71, p = 0.0025.
  • Interpretation-changing limitation: this was a phase 2 trial with a negative primary endpoint, and secondary/exploratory signals require confirmation in larger definitive trials before recommendations.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoTest whether 12 months of oral vitamin C (1000 mg/day) alters clonal growth dynamics (biological activity) in adults with CCUS or lower-risk myeloid malignancies versus placebo.Phase 2 randomized double-blind placebo-controlled trial (EVITA)Expand

In plain English

Phase 2 double-blind randomized placebo-controlled trial (EVITA) testing whether 12 months of oral vitamin C (1000 mg/day) alters clonal growth rate in adults with CCUS or lower-risk myeloid malignancies. 109 participants were randomized 1:1 to vitamin C (n=55) or placebo (n=54). The prespecified primary endpoint — median clonal growth rate from baseline to end of 12-month treatment — did not differ between groups. Secondary and exploratory outcomes reported differences in inflammatory cytokine trajectories, fewer serious adverse events with vitamin C, and longer overall survival in exploratory analyses.

Key findings

  • No difference in the prespecified primary endpoint (median clonal growth rate from baseline to end of 12-month treatment) between vitamin C and placebo.-0.016 (95% CI -0.096 to 0.064); p = .70
  • Fewer serious adverse events occurred in the vitamin C group than in the placebo group.18 of 55 (33%) vs. 30 of 53 (57%)
“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
What this piece can’t prove
  • Primary endpoint (clonal growth rate) was not met in this phase 2 trial.

2 further details could not be confirmed from the summary.

2human in vivoEvaluate clinical safety/tolerability of oral vitamin C versus placebo (including serious adverse events).Phase 2 randomized, double-blind, placebo-controlled trialExpand

In plain English

In the EVITA phase 2 double-blind randomized placebo-controlled trial of oral vitamin C (1000 mg/day) versus placebo for 12 months in adults with CCUS or lower-risk myeloid malignancies (n = 109 randomized), serious adverse events (SAEs) occurred less often in the vitamin C arm (18 of 55, 33%) than in the placebo arm (30 of 53, 57%). SAE reporting was a secondary outcome in the trial abstract; detailed harms ascertainment, definitions, and statistical testing for the SAE comparison are not provided in the abstract.

Key findings

  • Fewer participants experienced serious adverse events in the vitamin C arm than in the placebo arm during the treatment period.Counts: 18/55 (33%) vs 30/53 (57%); risk difference ≈ -24 percentage points; relative risk ≈ 0.58 (33%/57%).
“secondary outcomes included ... fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%])”
What this piece can’t prove

5 further details could not be confirmed from the summary.

3human in vivoAssess effects of oral vitamin C on inflammatory cytokine trajectories versus placebo.Double-blind randomized placebo-controlled phase 2 trial with longitudinal biomarker assessmentExpand

In plain English

In the EVITA double-blind, randomized, placebo-controlled phase 2 trial (n = 109), secondary outcomes reported differences in inflammatory cytokine trajectories between oral vitamin C (1000 mg/day) and placebo over 12 months. The abstract does not report which cytokines, the direction or magnitude of trajectory differences, or the statistical model details.

Key findings

  • Secondary outcomes reported differences in inflammatory cytokine trajectories between oral vitamin C (1000 mg/day) and placebo over the 12-month treatment period.
“secondary outcomes included differences in inflammatory cytokine trajectories”
What this piece can’t prove
  • As a secondary outcome in a phase 2 trial, findings may be exploratory and require confirmation in larger studies; the abstract does not report whether cytokine analyses were pre-specified.

2 further details could not be confirmed from the summary.

4human in vivoExplore longer-term clinical outcomes (e.g., overall survival) during follow-up comparing vitamin C versus placebo.Exploratory long-term follow-up time-to-event analysisExpand

In plain English

In the EVITA randomized, placebo-controlled phase 2 trial (oral vitamin C 1000 mg/day vs placebo for 12 months with subsequent long-term follow-up), an exploratory time-to-event analysis reported longer overall survival with vitamin C compared with placebo (hazard ratio 0.35; 95% CI 0.17–0.71; p = 0.0025). The analysis is described as exploratory in the abstract and details on the survival model, censoring, follow-up duration, and event counts are not provided in the abstract.

Key findings

  • In exploratory analyses of the randomized cohort during long-term follow-up, overall survival was significantly longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17–0.71); p = 0.0025
“In exploratory analyses, overall survival was significantly longer with VitC (hazard ratio, 0.35; 95% CI, 0.17 to 0.71; p = .0025).”
What this piece can’t prove
  • Abstract lacks critical time-to-event details: statistical model (e.g., Cox), proportional hazards assessment, censoring rules, number at risk, event counts, and median/maximum follow-up time.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 34 candidate papers

SelectedOpen access

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

Cancer · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Author response for "Impact of mixed nut consumption on faecal lipid content and gut microbiota composition in healthy adults"

2026 · Crossref

Source (opens in a new tab)
Candidate

Author response for "Enhancing Photodynamic and Chemodynamic Therapy Efficacy through a Novel ROS-Amplifying Therapeutic Platform for Breast Cancer Treatment"

2026 · Crossref

Source (opens in a new tab)

And 28 more candidates considered.